Brief: Resverlogix In Active Discussions With Morocco’S Ministry Of Health For Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone
01/11/2021 13:39
Nov 1 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX IN ACTIVE DISCUSSIONS WITH THE KINGDOM OF
MOROCCO’S
MINISTRY OF HEALTH FOR THE LAUNCH OF COVID-19 CLINICAL STUDIES
WITH FIRST-IN-CLASS DRUG APABETALONE
Source text for Eikon: ID:nGNX2xg0ww
Further company coverage: RVX.TO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment